Supernus Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $20.9M
Supernus Pharmaceuticals reported total revenues of $226.8 million for the third quarter of 2026, driven by net product sales and collaboration revenue from ZURZUVAE. While the company achieved net earnings of $20.9 million for the quarter, it recorded a net loss of $39.8 million for the first nine months of 2026, primarily due to $56.5 million in impairment charges.
- Key figure
- Net income $20.9M